Avstera Therapeutics Corp.
Monday, February 26, 2024
Uris
Oncology
At Avstera, our primary initial focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients who fail to respond to existing therapies, or end up developing resistance to immunotherapy. With our proprietary pipeline of oncology programs, including an ultra-specific immunomodulatory HDAC6i which has been IND cleared by FDA for FIH trials (AVS100), first in class myeloid cell therapy platform (AVS200), and mRNA cancer vaccine encoding TEM1 (AVS300), we will offer revolutionary solutions targeting solid tumors and addressing a significant unmet need for patients.
State
Pennsylvania
Country
United States
Website
http://www.avstera.com
CEO/Top Company Official
Avstera Therapeutics Corp.
Lead Product in Development
AVS100 - highly selective, orally bioavailable, brain penetrable HDAC6 inhibitor targeting solid tumors
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
3
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}